SMi are proud to present their 11th annual Clinical Trials in CNS conference, scheduled for the 5th and 6th of November, 2012.
With increasing average life expectancy, the wide range of potential disorders (from Alzheimer’s, to Parkinson’s, MS, dementia and depression) that arise from the multiple targets of the CNS, are becoming increasingly widespread in the population. This creates an ever greater need for new treatments and therapies in the industry. Clinical trials in the CNS industry must therefore operate the minefield of varying regulations, ethical and logistical difficulties, in order to develop a drug from discovery to market.
This year the SMi Group's Clinical Trials in CNS conference will cover the essential topics in the CNS industry, including: clinical trial optimisation, modelling and efficiency, preclinical discovery of biomarkers and implementation of these novel innovations as well as a talk on the safety of CNS drugs from a former member of the MHRA.
This groundbreaking conference will give delegates an opportunity to gain insights into the best practices in clinical trials, as well as examples and case studies of previous techniques and methods. This is an opportunity not to be missed, as we delve into the complex and exciting world of Central Nervous System discovery, allowing delegates to learn, explore and debate the key areas of CNS, its preclinical discovery and its clinical trials.
The Clinical Trials in CNS conference offers a fantastic opportunity to discuss and debate the industry's hot topics with the key members of the CNS industry. The conference is one not to be missed out on for anyone who is a member of the CNS, neurology or clinical trials industry.
- Discuss the best optimisation techniques for clinical trials: how to improve efficiency, adapt a clinical trial and ensure the smooth running of a trial via pre-clinical techniques
- Explore the latest innovations in pre-clinical discovery and biomarker identification and how these can lead to a more cost-effective and efficient clinical trial
- Evaluate the best mechanisms for implementation of theoretical ideas into the clinical trial, and how this will translate to a better clinical trial overall
- Learn of the latest drug developments combating the key diseases in CNS, from Alzheimer's and dementia, to depression and schizophrenia
- Hear talks on case studies of clinical trial results and developments, hearing firsthand experiences of how companies dealt with issues and managed clinical trials in specific diseases in the CNS industry
Industry Profile:
CEO’s, Executive Directors, Heads, Team Leaders and Consultants in the fields of:
- Clinical trial management and logistics
- CNS research
- Epigenetics in CNS disorders
- Research and development
- Pain therapeutics
- Biomarker discovery
- Preclinical optimisation and modelling
- Biobanking for research and development
- Clinical trial safety and evaluation
- Clinical trial design
- Biomarker research and development
- Treatment of Alzheimer's, Parkinson's, Dementia, multiple sclerosis, depression, schizophrenia, and other CNS disorders
Previous Companies in Attendance:
Abbott Laboratories; Alzheimer’s Research UK; AstraZeneca; Biogen Idec; Biomedical Systems Europe; Bracket Global; Bristol-Myers Squibb Pharmaceuticals Ltd; BTG; Cambridge Cognition ; Eli Lilly ; Eli Lilly & Company Ltd; F. Hoffmann - La Roche; Glaxo Manufacturing Services Limited; GLAXOSMITHKLINE; Grunenthal Gmbh; GSK; Hoffman La Roche; Imperial College London; Janssen Strategic Marketing; Kings College London; Lilly Research Centre Ltd; Maastricht University; Medicines & Healthcare Products Regulatory Agency (MHRA) ; Merck & Co; Merck Serono International S.A.; MRC Technology; MS4 Research Institute; MSD; Myriad RBM Inc; Myriad RBM, Inc.; Nuffield Depr of Clinical Nuerosciences, University of Oxford; Oxford University; Parexel International; Pfizer; Pfizer Regenerative Medicine; QCTR Ltd; Roche Products Ltd; SC Lorentina 2102 SRL; Servier Research & Development; Shire Pharmaceuticals Group Plc; South West DeNDRoN; Surrey Satellite Technology Ltd (S S T L); Takeda Pharmaceuticals Europe Ltd; United BioSource Corporation (UCB); University Claude Bernard of Lyon 1 ; University Of Bristol; University of Copenhagen; University of Glasgow and University of Oxford